<DOC>
	<DOCNO>NCT00133952</DOCNO>
	<brief_summary>The purpose study test hypothesis oral administration ruboxistaurin reduce occurrence sustain moderate visual loss ( SMVL ) patient clinically significant macular edema . SMVL define 15 letter decrease baseline best-corrected Early Treatment Diabetic Retinopathy Study ( ETDRS ) visual acuity sustain patient 's last 6 month study participation . The SMVL data study combine SMVL data Study B7A-MC-MBDL purpose compare ruboxistaurin placebo .</brief_summary>
	<brief_title>Effect Ruboxistaurin Clinically Significant Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>Type 1 2 diabetes 18 year old Hemoglobin A1c ( HbA1c ) less equal 11 % Mild severe nonproliferative diabetic retinopathy study eye Clinically significant macular edema study eye within 100 micron center macula Previous surgery laser treatment ( need laser treatment within 3 month ) study eye Glaucoma study eye Unstable cardiovascular disease Major surgery within past 3 month Significantly impair kidney liver function , malignancy require chemotherapy radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>